Patents by Inventor Thiago Trovati Maciel

Thiago Trovati Maciel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240025904
    Abstract: The present disclosure relates to PDE9 inhibitors, compositions comprising the PDE9 inhibitors, and methods of using the PDE9 inhibitors and compositions for treatment of cardiac failure.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 25, 2024
    Inventors: Rahul Dilip BALLAL, Thiago Trovati MACIEL, Deepak GUPTA, Thomas WANG
  • Publication number: 20230000838
    Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.
    Type: Application
    Filed: November 20, 2020
    Publication date: January 5, 2023
    Applicants: AB SCIENCE, UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Olivier HERMINE, Thiago TROVATI MACIEL, Slimane ALLALI, Rachel RIGNAULT-BRICARD, Caroline CARVALHO
  • Publication number: 20220047589
    Abstract: The present disclosure relates to PDE9 inhibitors, compositions comprising the PDE9 inhibitors, and methods of using the PDE9 inhibitors and compositions for treatment of thalassemia.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Inventors: Rahul Dilip BALLAL, Thiago Trovati MACIEL
  • Publication number: 20190049469
    Abstract: Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 14, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Publication number: 20180031579
    Abstract: The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 1, 2018
    Inventors: Ivan CRUZ-MOURA, Valérie BARDET, Michaël DUSSIOT, Thiago TROVATI MACIEL, Jérôme TAMBURINI, Norbert IFRAH, Olivier HERMINE
  • Publication number: 20170119804
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 4, 2017
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Publication number: 20150276766
    Abstract: Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 1, 2015
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • Publication number: 20150266950
    Abstract: Provided herein are methods for the treatment of anemia, wherein the methods comprise administration of antagonists of Growth differentiation factor 11 (GDF1 1; also known as bone morphogenetic protein 11 (BMP11)) to a subject in need of the treatment.
    Type: Application
    Filed: October 23, 2013
    Publication date: September 24, 2015
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • Publication number: 20150197574
    Abstract: The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders
    Type: Application
    Filed: August 2, 2013
    Publication date: July 16, 2015
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Michael Dussiot, Etienne Paubelle, Thiago Trovati Maciel